HOPKINTON, Mass. and SEOUL, Korea, Jan. 12, 2011 /PRNewswire/ —
Caliper Life Sciences, Inc. (Nasdaq:
CALP) and Seegene, Inc. (KOSDAQ: A096530) today announced that
they have entered into a strategic partnership to enable Seegene’s
SeePlex™ multiplex diagnostic assays to run on Caliper’s
innovative LabChip® Dx platform. The SeePlex assays will be
marketed and distributed outside of the United States in a
preferred partnership for use with the LabChip Dx through Seegene’s
extensive network of global distributors. The parties will
co-market Caliper’s LabChip Dx platform and Seegene’s complete line
of unique multiplex diagnostic content effective immediately, and
work together to implement specific content and platform technology
development efforts to expand the number of diagnostic tests
available, which will be offered in a unique, co-branded product
brochure. Seegene and Caliper intend to work together to
commercialize selected diagnostic assays with improved sensitivity
and specificity while reducing overall costs.
The LabChip Dx system, which includes specific diagnostic
identification, scoring and reporting software, developed in
collaboration with Seegene, is based on the same approach that has
become the standard, microfluidic based, electrophoretic separation
platform in life sciences research, enabling high throughput,
multiplex, cost effective sample processing for discovery and
validation of molecular and companion diagnostics. The
platform can analyze large numbers of multiplex samples using very
minimal volume of sample with automatic pipetting and avoids the
need to further purify or dilute diagnostic PCR products. The
cost-effective approach of Caliper’s robust microfluidics
technology explains its high rate of adoption among research
laboratories around the world.
Seegene’s proprietary technologies and products have b
‘/>”/>
SOURCE
